Gene fusions create entirely new proteins, allowing for highly specific drug targeting with a wider therapeutic window and fewer side effects. In contrast, point mutations are subtle changes to existing proteins, making it difficult to inhibit the mutant form without affecting the wild-type, leading to lower efficacy and more toxicity.
Unlike older HER2 tyrosine kinase inhibitors (TKIs) that also target EGFR, zungertinib is highly selective. This specificity prevents common EGFR-mediated side effects like severe diarrhea and acneform rash, resulting in a much better-tolerated treatment for patients with HER2-mutant lung cancer.
Resistance to the covalent HER2 inhibitor zungertinib can occur via mutations at its binding site (Cys-805). Because sevabertinib is a non-covalent inhibitor, it doesn't rely on this site for binding and may remain effective. This highlights a key mechanism-based sequencing strategy for HER2-targeted therapies.
Combining KRAS G12C inhibitors with checkpoint inhibitors increases the risk of transaminitis. Differentiating the causative agent is clinically challenging. A rapid recovery after stopping both drugs suggests the KRAS inhibitor is the cause and can be restarted at a lower dose; slower recovery points to the immunotherapy.
Despite a more challenging neurocognitive side effect profile, lorlatinib's median progression-free survival (PFS) of over seven years has shifted expert practice. This remarkable efficacy now positions it as the preferred first-line agent over better-tolerated second-generation TKIs for ALK-positive NSCLC.
With a 90% response rate and median progression-free survival approaching four years, taletrectinib is now the preferred frontline treatment for ROS1-positive NSCLC. Its efficacy and manageable safety profile, primarily transient GI toxicity and manageable LFT elevation, surpass older-generation inhibitors.
Selpercatinib can cause a rare but important side effect: chylous (lymphatic fluid) effusions in both the pleural and pericardial spaces. Clinicians must recognize this as a drug-induced toxicity and not misdiagnose it as cancer recurrence, as the condition is manageable with dose interruption or reduction.
A Phase 3 trial revealed that the RET inhibitor pralsetinib causes a higher rate of severe and opportunistic infections than chemotherapy. This suggests significant immunomodulatory effects beyond neutropenia. This surprising safety finding makes selpercatinib the more favorable RET inhibitor for treating NSCLC.